Movano (NASDAQ:MOVE – Get Rating) and Nuwellis (NASDAQ:NUWE – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Insider & Institutional Ownership
16.5% of Movano shares are held by institutional investors. Comparatively, 29.9% of Nuwellis shares are held by institutional investors. 6.1% of Movano shares are held by insiders. Comparatively, 0.4% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Movano and Nuwellis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nuwellis has a consensus price target of $7.50, suggesting a potential upside of 646.27%. Given Nuwellis’ higher probable upside, analysts clearly believe Nuwellis is more favorable than Movano.
Earnings and Valuation
This table compares Movano and Nuwellis’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nuwellis||$7.92 million||1.27||-$19.58 million||($3.13)||-0.32|
Nuwellis has higher revenue and earnings than Movano. Movano is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
This table compares Movano and Nuwellis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Nuwellis beats Movano on 6 of the 11 factors compared between the two stocks.
About Movano (Get Rating)
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
About Nuwellis (Get Rating)
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.